English
- English
- 中文
Pamedic | Products
PanMediso | Science, innovation and technology
OUR BUSINESS
Pamedic focuses on the research and production of experimental anticancer drugs. The PM process stands out in global Ac-225 production, offering high purity, large output, low radiation, low pollution, reduced raw material consumption, and cost advantages. It has successfully achieved small-scale experimentation.
Medical Isotope Development
Focusing on Ac-225 and Ge-68, we provide end-to-end solutions from isotope R&D and production to radiopharmaceutical assembly.
Clinical Applications & Partnerships
Working independently or with radiopharmaceutical manufacturers, we collaborate with hospitals to deliver nuclear medicine therapies in real-world clinical settings.
CDMO Services
From small-scale lab research to large-scale commercial production, we offer customized manufacturing services to reduce R&D costs and accelerate drug commercialization.
Innovative Radiopharmaceuticals
Our pipeline targets tumor-specific antigens with novel therapies based on Ac-225 and Ge-68, advancing precision diagnosis and treatment in nuclear medicine.
医用同位素的研发、生产及销售
·医用同位素Ac-225和Ge-68的研发、生产及销售;
·为核药企业提供从医用同位素下线到核药装配的一体化解决方案。
CDMO业务
·为客户提供从小规模实验室级别到大规模商业生产的定制服务。节省研发成本，加速新药上市进程;
·提供先进的核医学解决方案，以支持诊断和治疗领域的创新发展。
核药临床应用及推广
自主或联合核药生产商通过自主研发或技术引进等方式生产核药，与所合作的医院建立合作关系，提供专业核医学治疗，医院负责提供核药的临床应用场景。
核药研发及生产
核药创新药的研发及生产。包括放射性同位素的选择、药物设计、以及与肿瘤特有抗原结合的分子的开发，选择以Ac-225和 Ge-68为靶向核素的创新药管线进行研发。
Applications of Medical Radioisotopes
Targeted Radionuclide Therapy in Oncology
Clinical Trials
Radioligand therapy (RLT) for advanced prostate cancer utilizes ligands targeting prostate-specific membrane antigen (PSMA) on the surface of cancer cells. By delivering therapeutic radioisotopes directly to tumor sites and metastases, RLT effectively destroys malignant cells [101], while also helping to relieve pain and other clinical symptoms associated with metastatic prostate cancer.
Diagnostic Imaging
For diagnostic radiopharmaceuticals, nuclear medicine imaging enables localization and monitoring of tumor cells after treatment with various therapeutic approaches—such as chemotherapy, targeted therapy, antibody-based therapy, or cell therapy—selected according to the stage of tumor development. By combining diagnostic imaging with targeted therapies, this approach supports precision medicine, allowing accurate assessment of therapeutic response and tailored patient care.
Research and Development
In the development of nuclear medicine formulations, efforts focus not only on meeting clinical needs but also on improving ligand targeting and the specificity of radionuclide-induced cytotoxicity. These advancements aim to enhance the accuracy of tumor diagnosis and treatment, while also addressing the challenges of treating solid tumors.
Approved Therapeutics
Radionuclide receptor-targeted therapy is a treatment approach that employs radiolabeled ligands to specifically bind receptors on the surface of cancer cells. Using PET/CT to evaluate treatment response, this method delivers a concentrated internal radiation dose directly to tumor sites, effectively destroying malignant cells while sparing surrounding healthy tissue.
Email: pchl@pamedicholdings.com
Address: Room 406, Building C, Hetao Innovation Center No. 1 Honghua
Road, Fubao Subdistrict Futian District, Shenzhen, China
Copyright@2025 PanMediso
